about
Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94).Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer.Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06).Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.The relationship of health/food literacy and salt awareness to daily sodium and potassium intake among a workplace population in Switzerland.Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).A short food literacy questionnaire (SFLQ) for adults: Findings from a Swiss validation study.Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.Study design and baseline characteristics of a combined educational and environmental intervention trial to lower sodium intake in Swiss employees.Neo-adjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.In Regard to Pisansky et al.Reply to C. Cozzarini et al.Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal ExcisionImpact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III TrialNonparametric Location Estimators in the Randomized Complete Block DesignFeasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practiceWhat can we learn from the ZOOM trial?Depth of cure of resin composites: Is the ISO 4049 method suitable for bulk fill materials?Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trialEffectiveness and Feasibility of a Remote Lifestyle Intervention by Dietitians for Overweight and Obese Adults: Pilot StudyReply by AuthorsPrognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapyHigh thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudyRE-AIM evaluation of a one-year trial of a combined educational and environmental workplace intervention to lower salt intake in SwitzerlandSAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic modelRisk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series DataShort regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyQuality of Life After Total Mesorectal Excision and Rectal Replacement: Comparing Side-to-End, Colon J-Pouch and Straight Colorectal Reconstruction in a Randomized, Phase III Trial (SAKK 40/04)Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous fail
P50
Q35073721-44C4EE34-B0BF-44D1-AEC9-5C216359638DQ35830105-5CCD7456-168D-40F2-8FA6-042D56A5544AQ36227221-FA4DCB96-E58A-4068-B272-C101A70E0862Q36263732-40F1E9F8-BE5C-470C-B97E-050BD7A93CCEQ38215073-7DD1E432-0166-4CD6-AA7C-2594EF0B9E62Q38437850-5781147F-187F-4CC9-8475-686603C06D8AQ38662705-208C3D53-DD86-4DB8-BC4F-669F80C4F698Q39031270-238ED2DF-2D56-41FC-8D78-3E710E0FC6ACQ39669627-1EE4A0C0-5587-4125-8430-5F34CC61A1AEQ40162858-FADFDD10-5066-4BA0-8DA1-04119554F071Q47195781-B7CEFF5F-FDEB-484F-B249-73DEC38144ADQ47642783-8E281D30-A91D-42F8-BBC6-31A8898AB184Q47694157-40EF9E81-8601-45C8-9410-EEF18F2DFB00Q50150691-25D7F804-2A25-467B-8A5D-E5AEBEF1F3A9Q51731400-D72F385B-C9D2-4B69-8B00-75410A690925Q52805565-C134F2A8-F829-4D5C-9457-89D5CEBED772Q52838943-085956E6-457B-4D72-9C08-446F5C1A78A6Q52842747-6D0E7674-860E-4124-81A6-3479F3947444Q52855256-684150B7-C64E-4A9A-B8CE-A8932E743C2DQ54134070-A1DD2997-D83B-4065-AF7F-D09D4798D10DQ57664215-65353994-BDB3-4939-ADC1-C6E26C75A193Q57664218-B18E8C65-D52E-44D3-88A8-ABFF839D063DQ57664239-F75AD312-F3A9-4CCD-9920-4961D61877FBQ57664242-E08F407B-148E-4178-ACE0-81EC1A92D9FFQ57664244-586B8E7E-2474-4AFD-9C4D-93C52D6918E3Q57664245-B22E6BCE-B005-4621-B7F3-75A7CB3E75DAQ59794738-61AFBF13-757F-4799-838D-44DBE92A6F1CQ64055843-92C4ECE0-DD6F-478D-A74D-33BCA40F11DCQ89464114-B359889E-F764-4A70-9F1B-4487A9995040Q89505951-44D9496E-4B56-4DAA-B622-1BF75C802BB5Q89945020-C863C758-4528-4DE0-BA44-F1D6C411AE61Q90066574-3C4C4C42-6DBA-4BA9-B55F-1298E554EAB8Q90088254-C8348F9D-3577-4296-B656-BFBDCFAD6CB6Q90505811-2F0AD060-F9F5-44FB-A6EB-04E47C51FD86Q92039024-C919B4CD-82A8-4EEC-AF28-51457605284EQ92123981-CDA34034-6C3D-4907-8488-FA645D7B38A7Q92951200-1259038B-96F5-4649-8D7F-876005F4A69AQ94503535-2B3F8CB4-9F72-406F-B0F7-6166039AECA6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
S Hayoz
@ast
S Hayoz
@en
S Hayoz
@es
S Hayoz
@nl
type
label
S Hayoz
@ast
S Hayoz
@en
S Hayoz
@es
S Hayoz
@nl
altLabel
Stefanie Hayoz
@en
prefLabel
S Hayoz
@ast
S Hayoz
@en
S Hayoz
@es
S Hayoz
@nl
P106
P1153
55035921800
P31
P496
0000-0002-2265-6559